101 results
8-K
EX-99.1
PRTA
Prothena Corporation plc
8 May 24
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
4:09pm
from collaboration revenue from Bristol Myers Squibb.
Research and development (R&D) expenses totaled $64.1 million for the first quarter of 2024 … , as compared to $44.8 million for the first quarter of 2023. The increase in R&D expenses for the first quarter of 2024 compared to the same period
8-K
EX-99.1
PRTA
Prothena Corporation plc
15 Feb 24
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
4:09pm
.
Research and development (R&D) expenses totaled $61.9 million and $220.6 million for the fourth quarter and full year of 2023, respectively, as compared … to $36.9 million and $135.6 million for the fourth quarter and full year of 2022, respectively. The increase in R&D expense for the fourth quarter
8-K
EX-99.1
q4isq
2 Nov 23
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
4:09pm
8-K
EX-99.1
q8jgxrq
3 Aug 23
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
4:10pm
8-K
EX-99.1
jctirmm
4 May 23
Prothena Reports First Quarter 2023 Financial Results and Business Highlights
4:08pm
8-K
EX-99.1
lvbuqbzc
3 Nov 22
Prothena Reports Third Quarter 2022 Financial Results and Business Highlights
4:24pm
8-K
EX-99.1
m81r6h9i gd08oritf94
8 Aug 22
Prothena Reports Second Quarter 2022 Financial Results and Business Highlights
4:27pm
8-K
EX-99.1
f4pdsn9aj 07
5 May 22
Prothena Reports First Quarter 2022 Financial Results and Business Highlights
12:00am